C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter H—Medical DevicesPart 807—Establishment Registration and Device Listing for Manufacturers and Initial Importers of DevicesSubpart E—Premarket Notification Procedures

21 C.F.R. § 807.100 (2026)

FDA action on a premarket notification

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1994–2026 23citing cases
At a glance

Courts have cited this section in 23 opinions since 1994, 3 of them in the last five years. The most litigated part is subsection (a) (1 case).

(a) After review of a premarket notification, FDA will:

(1) Issue an order declaring the device to be substantially equivalent to a legally marketed predicate device;

(2) Issue an order declaring the device to be not substantially equivalent to any legally marketed predicate device;

(3) Request additional information; or

(4) Withhold the decision until a certification or disclosure statement is submitted to FDA under part 54 of this chapter.

(5) Advise the applicant that the premarket notification is not required. Until the applicant receives an order declaring a device substantially equivalent, the applicant may not proceed to market the device.

(b) FDA will determine that a device is substantially equivalent to a predicate device using the following criteria:

(1) The device has the same intended use as the predicate device; and

(2) The device:

(i) Has the same technological characteristics as the predicate device; or

(ii)(A) Has different technological characteristics, such as a significant change in the materials, design, energy source, or other features of the device from those of the predicate device;

(B) The data submitted establishes that the device is substantially equivalent to the predicate device and contains information, including clinical data if deemed necessary by the Commissioner, that demonstrates that the device is as safe and as effective as a legally marketed device; and

(C) Does not raise different questions of safety and effectiveness than the predicate device.

(3) The predicate device has not been removed from the market at the initiative of the Commissioner of Food and Drugs or has not been determined to be misbranded or adulterated by a judicial order.

[57 FR 58403, Dec. 10, 1992, as amended at 63 FR 5253, Feb. 2, 1998]
The 20 cases that cite 21 C.F.R. § 807.100 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENPhotoMedex, Inc. v. Irwin, 601 F.3d 919 (9th Cir. 2010).
cites § 807.100 1×cited by 57 cases
Where it cites § 807.100
“§ 360 (k); 21 C.F.R. § 807.100 . In other words, that device receives “510(k) clearance” and can be put on the market.”
The case’s holding
A private Lanham Act action is barred if the claim requires litigation of an underlying Food, Drug, and Cosmetic Act violation that the FDA has not concluded occurred.
Later courts cite it for
“because the fdca forbids private rights of action under that statute, a private action brought under the lanham act may not be pursued when, as here, the claim would require litigation of the alleged underlying fdca violation in a circumstance where the fda has not itself concluded that there was such a violation.” · 11 citing courts
2
GREENIvy Sports Med., LLC v. Sylvia Mathews Burwell, 767 F.3d 81 (D.C. Cir. 2014).
cites § 807.100 1×cited by 37 cases
Where it cites § 807.100
“See 21 C.F.R. § 807.100 . But if FDA disagrees with the proposed classification, the device 5 remains in Class III and must go through the pre-market approval process, unless FDA subsequently approves a petition for de novo classification.”
The case’s holding
An agency cannot use inherent reconsideration authority to reverse a decision when Congress has provided a specific statutory mechanism to rectify the agency's mistakes.
Later courts cite it for
“administrative agencies are assumed to possess at least some inherent authority to revisit their prior decisions, at least if done in a timely fashion.” · 12 citing courts
3
GREENRodriguez v. Stryker Corp., 680 F.3d 568 (6th Cir. 2012).
cites § 807.100 1×cited by 29 cases
Where it cites § 807.100
“§ 360(k); 21 C.F.R. § 807.100 . Stryker received permission through the 510(k) process to market its pump with a single indication for use: “to provide continuous infusion of a local anesthetic directly into the intra-operative site for postoperative pain management.”
The case’s holding
A manufacturer must exercise ordinary and reasonable care in testing a product for potential danger but is not liable for failing to warn of risks not reasonably foreseeable.
Later courts cite it for
“exercise of ordinary and reasonable care in testing a product for potential danger.” · 2 citing courts
4
GREENIn re Cryomedical Sciences, Inc. Sec. Litig., 884 F. Supp. 1001 (D. Md. 1995).
cites § 807.100 2×cited by 13 cases
Where it cites § 807.100
“4 21 C.F.R. §§ 807.100 (a), 814.1(e); 21 U.”
5
GREENUnited States v. Facteau, 89 F.4th 1 (1st Cir. 2023).
cites § 807.100 1×cited by 8 cases
Where it cites § 807.100
“§ 360c(i)(1)(A); 21 C.F.R. § 807.100 (b). At least ninety days before introducing a new device to the market, a manufacturer seeking § 510(k) clearance must submit a premarket notification to the FDA.”
Later courts cite it for
“make apparent his theory of the district court's plain error, and he did squarely address the plain error factors in his reply brief,” · 1 citing court
6
GREENCardioVention, Inc. v. Medtronic, Inc., 483 F. Supp. 2d 830 (D. Minn. 2007).
cites § 807.100 1×cited by 15 cases
Where it cites § 807.100
“21 C.F.R. § 807.100 (b). CardioVention asserts that Medtronic’s 510(k) submission to the FDA is relevant because it lists CardioVention’s CORx as a “predicate device” and characterizes it as “substantially equivalent” to the Resting Heart.”
Later courts cite it for
“courts have repeatedly refused to allow fda 510(k) notification of substantial equivalence as admission of infringement in patent cases.” · 2 citing courts
7
GREENUnited States v. Snoring Relief Labs Inc., 210 F.3d 1081 (9th Cir. 2000).
cites § 807.100 1×cited by 13 cases
Where it cites § 807.100
“See 21 C.F.R. § 807.100 . Snoring Relief tried to become the first company to market a self-fitting, anti-snoring mouthpiece without a prescription.”
Later courts cite it for
“most importantly, 'review under the arbitrary and capricious standard is narrow, and the reviewing court may not substitute its judgment for that of the agency.” · 2 citing courts
8
GREENGinochio v. Surgikos, Inc., 864 F. Supp. 948 (N.D. Cal. 1994).
cites § 807.100 1×cited by 13 cases
Where it cites § 807.100
“see also 21 C.F.R. § 807.100 (b). 5 . Defendants cite some regulations which are not general controls but which are discretionary, but do not argue that the FDA has applied them to the Mieroloc device.”
9
GREENIvy Sports Med., LLC v. Burwell, 174 F. Supp. 3d 130 (D.D.C. 2016).
cites § 807.100 1×cited by 3 cases
Where it cites § 807.100
“If the FDA determines that the device is substantially equivalent to an existing device, the agency issues a classification order “declaring the device to be substantially equivalent'to a legally marketed predicate device,” 21 C.F.R. § 807.100 (a)(1), which “allow[s] the *134…”
10
GREENBaker v. Danek Med., 35 F. Supp. 2d 865 (N.D. Fla. 1998).
cites § 807.100 2×cited by 4 cases
Where it cites § 807.100
“§§ 360c(c)(2)(C),(f)(1); 21 C.F.R. § 807.100 (b). Because substantial equivalence is governed by Section 510(k) of the FDCA, 21 U.”
11
GREENIvy Sports Med., LLC v. Sebelius, 938 F. Supp. 2d 47 (D.D.C. 2013).
cites § 807.100 1×cited by 4 cases
Where it cites § 807.100
“See also 21 C.F.R. § 807.100 (b). If the agency determines a new device is substantially equivalent to a predicate device, the new device is cleared and subject to the same regulatory Class controls as the predicate.”
12
GREENJames v. Diva Int'l, Inc., 803 F. Supp. 2d 945 (S.D. Ind. 2011).
cites § 807.100 1×cited by 3 cases
Where it cites § 807.100
“21 C.F.R. § 807.100 . Additionally, the FDA regulations govern the form and substance of the information required for a submission under Section 510(k), including proposed labeling.”
13
GREENZeltiq Aesthetics, Inc. v. BTL Indus., Inc., 32 F. Supp. 3d 1088 (N.D. Cal. 2014).
cites § 807.100 2×cited by 1 case
Where it cites § 807.100
“§ 360c(i)(l)(A); see also 21 C.F.R. § 807.100 (“FDA will determine that a device is substantially equivalent to a predicate device .”
14
YELLOWDuvall v. Bristol-Myers-Squibb Co., 65 F.3d 392 (4th Cir. 1995).
cites § 807.100 1×cited by 17 cases
Vacated: 2 citing opinions add another limit ("vacated (caution)").
Summary
No passage or summary on file for this case yet.
15
GREENCatherine W. Griffin v. Medtronic, Inc., 82 F.3d 79 (4th Cir. 1996).
cites § 807.100 1×cited by 2 cases
Where it cites § 807.100
“However, the prosthesis was brought to market via the "substantially equivalent” mechanism outlined at 21 C.F.R. § 807.100 (a) (1995). Id. Under this administrative regime, a Class III device for which the FDA does not yet require the usual premarket approval may be marketed if…”
16
GREENDow v. Baxter Healthcare Corp., 899 F. Supp. 822 (D. Mass. 1995).
cites § 807.100 1×cited by 1 case
Where it cites § 807.100
“21 C.F.R. § 807.100 . The process has been described as follows: Under section 510(k), devices that are shown to be substantially equivalent to a device on the market before the MDA [was] passed (a “predicate” device) can gain approval without submitting to the type of premarket…”
17
NEUTRALSylvester v. Mentor Corp., 663 So. 2d 176 (La. Ct. App. 1995).
cites § 807.100 1×cited by 4 cases
Summary
No passage or summary on file for this case yet.
18
GREENIn re Orthopedic Bone Screw Prods. Liab. Litig., 193 F.3d 781 (3d Cir. 1999).
cites § 807.100 1×cited by 1 caseunknown
Where it cites § 807.100
“§ 360e(b)(1)(B); 21 C.F.R. § 807.100 (b). A determination of substantial equivalence is called “510(k) clearance” in reference to the applicable section of the original Act.”
The case’s holding
A civil conspiracy claim cannot rest solely on violation of a federal statute that creates no private right of action; an independent underlying tort is required.
19
NEUTRALDawson v. Howmedica, Inc., 886 F. Supp. 1402 (E.D. Tenn. 1995).
cites § 807.100 1×cited by 1 case
Where it cites § 807.100
“§§ 360c(a)(1)(C), 360e(b); 21 C.F.R. § 807.100 . An important exception to this general rule exists for experimental devices undergoing scientific investigation.”
20
NO FLAGTelebrands Corp. v. VindEx Solutions LLC, No. 5:21-cv-00898 (N.D. Cal. Apr. 8, 2022).
cites § 807.100 1×cited by 0 casesunknown
Where it cites § 807.100
“See 21 C.F.R. § 807.100 (b). 3 B. Factual Background 4 Defendants are Chinese corporations with their principal places of business in China.”

Show all 23 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199420102026

One bar per year. Tallest: 5 cases in 1995. 2026 is a partial year. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
4th Cir.3N.D. Cal.36th Cir.29th Cir.2D.D.C.21st Cir.13rd Cir.1D.C. Cir.1

The 8 courts with the most citing cases, of 16 courts in all.

By subsection
(a)1 case
Griffin v. Medtronic Inc, No. 94-1219 (4th Cir. Apr. 30, 1996).

Show all 23 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com